Search Login Register
Diffuse Cutaneous Leishmaniasis
Summary
48
relevant articles (4 outcomes,
2 trials/studies)
found for this Disease
Description:
A form of LEISHMANIASIS, CUTANEOUS caused by Leishmania aethiopica in Ethiopia and Kenya, L. pifanoi in Venezuela, L. braziliensis in South America, and L. mexicana in Central America. This disease is characterized by massive dissemination of skin lesions without visceral involvement.
Also Known As:
Leishmaniasis, Diffuse Cutaneous; Cutaneous Leishmaniases, Diffuse; Cutaneous Leishmaniasis, Diffuse; Diffuse Cutaneous Leishmaniases; Leishmaniases, Diffuse Cutaneous
Key Drugs and Agents for Diffuse Cutaneous Leishmaniasis
Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
-
Pentamidine (NebuPent)
:
1 outcome in 4 results
:
FDA 6
Generic
-
Allopurinol (Remid)
:
1 outcome in 2 results
:
FDA 25
Generic
-
Tamoxifen
:
1 outcome in 1 result
:
FDA 12
Generic
-
Antigens
:
1 study in 17 results
: IBA
-
Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
:
1 study in 1 result
: IBA
-
HLA-DR Antigens (HLA-DR)
:
1 study in 1 result
: IBA
-
Antibodies
:
5 results
: IBA
-
miltefosine
:
4 results
: IBA
-
Immunoglobulin G (IgG)
:
3 results
: IBA
-
Carbon Monoxide
:
2 results
: IBA
Show All >>
Diseases Related to Diffuse Cutaneous Leishmaniasis
-
Cutaneous Leishmaniasis
-
Leishmaniasis
-
Visceral Leishmaniasis (Kala Azar)
-
Mucocutaneous Leishmaniasis
-
Lepromatous Leprosy
Show All >>
Key Therapies for Diffuse Cutaneous Leishmaniasis
Efficacy Chart >>
-
Drug Therapy (Chemotherapy)
:
2 outcomes in 4 results
-
Immunotherapy
:
2 outcomes in 3 results
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2008 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.